Trial
NCT06160609
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
Belantamab Mafodotin
Why stopped
The study was terminated due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-12